vorinostat has been researched along with Huntington Disease in 6 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using Alzheimer's disease and Huntington's disease as examples in the following article, some of latest data linking both the histone code and the various proteins that regulate this code to the pathogenesis of neurological disease are discussed." | 2.47 | Epigenetic treatment of neurological disease. ( Gray, SG, 2011) |
| "We use a Drosophila Huntington's disease model to establish dose regimens and protocols to assess the effectiveness of drug combinations used at low threshold concentrations." | 1.33 | Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. ( Agrawal, N; Apostol, BL; Bodai, L; Chang, LW; Chiang, AS; Marsh, JL; Pallos, J; Slepko, N; Thompson, LM, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bürli, RW | 1 |
| Luckhurst, CA | 1 |
| Aziz, O | 1 |
| Matthews, KL | 1 |
| Yates, D | 1 |
| Lyons, KA | 1 |
| Beconi, M | 1 |
| McAllister, G | 1 |
| Breccia, P | 1 |
| Stott, AJ | 1 |
| Penrose, SD | 1 |
| Wall, M | 1 |
| Lamers, M | 1 |
| Leonard, P | 1 |
| Müller, I | 1 |
| Richardson, CM | 1 |
| Jarvis, R | 1 |
| Stones, L | 1 |
| Hughes, S | 1 |
| Wishart, G | 1 |
| Haughan, AF | 1 |
| O'Connell, C | 1 |
| Mead, T | 1 |
| McNeil, H | 1 |
| Vann, J | 1 |
| Mangette, J | 1 |
| Maillard, M | 1 |
| Beaumont, V | 1 |
| Munoz-Sanjuan, I | 1 |
| Dominguez, C | 1 |
| Gray, SG | 1 |
| Mielcarek, M | 1 |
| Benn, CL | 1 |
| Franklin, SA | 1 |
| Smith, DL | 2 |
| Woodman, B | 2 |
| Marks, PA | 2 |
| Bates, GP | 2 |
| Hockly, E | 1 |
| Richon, VM | 1 |
| Zhou, X | 1 |
| Rosa, E | 1 |
| Sathasivam, K | 1 |
| Ghazi-Noori, S | 1 |
| Mahal, A | 1 |
| Lowden, PA | 1 |
| Steffan, JS | 1 |
| Marsh, JL | 2 |
| Thompson, LM | 2 |
| Lewis, CM | 1 |
| Agrawal, N | 1 |
| Pallos, J | 1 |
| Slepko, N | 1 |
| Apostol, BL | 1 |
| Bodai, L | 1 |
| Chang, LW | 1 |
| Chiang, AS | 1 |
| Dompierre, JP | 1 |
| Godin, JD | 1 |
| Charrin, BC | 1 |
| Cordelières, FP | 1 |
| King, SJ | 1 |
| Humbert, S | 1 |
| Saudou, F | 1 |
1 review available for vorinostat and Huntington Disease
| Article | Year |
|---|---|
Epigenetic treatment of neurological disease.
Topics: Alzheimer Disease; Butylamines; Cell Differentiation; Endoplasmic Reticulum Stress; Epigenesis, Gene | 2011 |
5 other studies available for vorinostat and Huntington Disease
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
Topics: Animals; Dose-Response Relationship, Drug; Drug Design; Histone Deacetylase Inhibitors; Histone Deac | 2013 |
SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.
Topics: Animals; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Down-Regulation; Exons; Histone | 2011 |
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.
Topics: Acetylation; Animals; Base Sequence; Blood-Brain Barrier; Brain; Disease Models, Animal; DNA Primers | 2003 |
Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila.
Topics: Amides; Animals; Benzoquinones; Disease Models, Animal; Drosophila; Drug Therapy, Combination; Femal | 2005 |
Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation.
Topics: Acetylation; Animals; Biological Transport, Active; Brain-Derived Neurotrophic Factor; Cell Line; Ce | 2007 |